Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease
A new drug delivery system is developed for ropinirole (RP) for the treatment of Parkinson’s disease (PD) consisting of biodegradable poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs). The formulation selected was prepared with 8 mg RP and 50 mg PLGA 502. This formulation exhibited mean enc...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-01-01
|
| Series: | Drug Delivery |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/10717544.2017.1359862 |
| _version_ | 1819099646636589056 |
|---|---|
| author | Emilia Barcia Liudmila Boeva Luis García-García Karla Slowing Ana Fernández-Carballido Yaquelyn Casanova Sofía Negro |
| author_facet | Emilia Barcia Liudmila Boeva Luis García-García Karla Slowing Ana Fernández-Carballido Yaquelyn Casanova Sofía Negro |
| author_sort | Emilia Barcia |
| collection | DOAJ |
| description | A new drug delivery system is developed for ropinirole (RP) for the treatment of Parkinson’s disease (PD) consisting of biodegradable poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs). The formulation selected was prepared with 8 mg RP and 50 mg PLGA 502. This formulation exhibited mean encapsulation efficiency of 74.8 ± 8.2%, mean particle size lower than 155 nm, the zeta potential of −14.25 ± 0.43 mV and zero-order in vitro release of RP (14.13 ± 0.17 μg/h/10 mg NPs) for 5 d. Daily doses of the neurotoxin rotenone (2 mg/kg) given i.p. to male Wistar rats induced neuronal and behavioral changes similar to those of PD. Once neurodegeneration was established (15 d) animals received RP in saline (1 mg/kg/d for 35 d) or encapsulated within PLGA NPs (amount of NPs equivalent to 1 mg/kg/d RP every 3 d for 35 d). Brain histology and immunochemistry (Nissl-staining, glial fibrillary acidic protein and tyrosine hydroxylase immunohistochemistry) and behavioral testing (catalepsy, akinesia, rotarod and swim test) showed that RP-loaded PLGA NPs were able to revert PD-like symptoms of neurodegeneration in the animal model assayed. |
| first_indexed | 2024-12-22T00:50:11Z |
| format | Article |
| id | doaj.art-b7d65e48a86143449b9ce4899ac500a5 |
| institution | Directory Open Access Journal |
| issn | 1071-7544 1521-0464 |
| language | English |
| last_indexed | 2024-12-22T00:50:11Z |
| publishDate | 2017-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Drug Delivery |
| spelling | doaj.art-b7d65e48a86143449b9ce4899ac500a52022-12-21T18:44:27ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642017-01-012411112112310.1080/10717544.2017.13598621359862Nanotechnology-based drug delivery of ropinirole for Parkinson’s diseaseEmilia Barcia0Liudmila Boeva1Luis García-García2Karla Slowing3Ana Fernández-Carballido4Yaquelyn Casanova5Sofía Negro6Universidad Complutense de MadridUniversidad Complutense de MadridUnidad de Cartografía Cerebral, Instituto Pluridisciplinar, Universidad Complutense de MadridUniversidad Complutense de MadridUniversidad Complutense de MadridUniversidad Complutense de MadridUniversidad Complutense de MadridA new drug delivery system is developed for ropinirole (RP) for the treatment of Parkinson’s disease (PD) consisting of biodegradable poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs). The formulation selected was prepared with 8 mg RP and 50 mg PLGA 502. This formulation exhibited mean encapsulation efficiency of 74.8 ± 8.2%, mean particle size lower than 155 nm, the zeta potential of −14.25 ± 0.43 mV and zero-order in vitro release of RP (14.13 ± 0.17 μg/h/10 mg NPs) for 5 d. Daily doses of the neurotoxin rotenone (2 mg/kg) given i.p. to male Wistar rats induced neuronal and behavioral changes similar to those of PD. Once neurodegeneration was established (15 d) animals received RP in saline (1 mg/kg/d for 35 d) or encapsulated within PLGA NPs (amount of NPs equivalent to 1 mg/kg/d RP every 3 d for 35 d). Brain histology and immunochemistry (Nissl-staining, glial fibrillary acidic protein and tyrosine hydroxylase immunohistochemistry) and behavioral testing (catalepsy, akinesia, rotarod and swim test) showed that RP-loaded PLGA NPs were able to revert PD-like symptoms of neurodegeneration in the animal model assayed.http://dx.doi.org/10.1080/10717544.2017.1359862ropinirolenanoparticlespoly (d,l-lactide-co-glycolide)parkinson’s disease |
| spellingShingle | Emilia Barcia Liudmila Boeva Luis García-García Karla Slowing Ana Fernández-Carballido Yaquelyn Casanova Sofía Negro Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease Drug Delivery ropinirole nanoparticles poly (d,l-lactide-co-glycolide) parkinson’s disease |
| title | Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease |
| title_full | Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease |
| title_fullStr | Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease |
| title_full_unstemmed | Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease |
| title_short | Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease |
| title_sort | nanotechnology based drug delivery of ropinirole for parkinson s disease |
| topic | ropinirole nanoparticles poly (d,l-lactide-co-glycolide) parkinson’s disease |
| url | http://dx.doi.org/10.1080/10717544.2017.1359862 |
| work_keys_str_mv | AT emiliabarcia nanotechnologybaseddrugdeliveryofropiniroleforparkinsonsdisease AT liudmilaboeva nanotechnologybaseddrugdeliveryofropiniroleforparkinsonsdisease AT luisgarciagarcia nanotechnologybaseddrugdeliveryofropiniroleforparkinsonsdisease AT karlaslowing nanotechnologybaseddrugdeliveryofropiniroleforparkinsonsdisease AT anafernandezcarballido nanotechnologybaseddrugdeliveryofropiniroleforparkinsonsdisease AT yaquelyncasanova nanotechnologybaseddrugdeliveryofropiniroleforparkinsonsdisease AT sofianegro nanotechnologybaseddrugdeliveryofropiniroleforparkinsonsdisease |